A phase II study of adjuvant gemcitabine/capecitabine and bevacizumab for patients treated neoadjuvantly chemotherapy for early stage breast cancer with high risk for relapse.

Trial Profile

A phase II study of adjuvant gemcitabine/capecitabine and bevacizumab for patients treated neoadjuvantly chemotherapy for early stage breast cancer with high risk for relapse.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Gemcitabine (Primary)
  • Indications Early breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top